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In this issue of Immunity, Escobar et al. (2014) bring microRNAs and chromatin together by showing how
activation-induced miR-155 targets the chromatin protein Jarid2 to regulate proinflammatory cytokine pro-
duction in T helper 17 cells.MicroRNAs are small noncoding RNAs
that control gene expression by de-
stabilizing protein-coding mRNAs and
reducing their translation. The microRNA
miR-155 is derived from the non-protein-
coding transcript of Bic, an oncogene
that promotes the development of B cell
lymphomas in mice and humans. miR-
155 is of interest to immunologists
because it is induced by signals that acti-
vate T cells, B cells and antigen-present-
ing cells, and regulates many aspects of
the immune response such as the ger-
minal center reaction and the differentia-
tion of T regulatory (Treg) cells and CD4+
T helper (Th) cells (Thai et al., 2007;
O’Connell et al., 2010; Oertli et al., 2011;
Lu et al., 2009; Kohlhaas et al., 2009).
In previous studies, miR-155 was re-
quired for the differentiation of inflamma-
tory Th1 and Th17 cells in experimental
autoimmune encephalomyelitis (O’Con-
nell et al., 2010) and Helicobacter pylori
infection (Oertli et al., 2011). Escobar
et al. (2014) now demonstrate that
both Th1 and Th17 cells develop during
Toxoplasma gondii infections in miR-
155-deficient mice. However, miR-155-
deficient CD4+RORgt+ cells are defective
in the expression of Il22, Il10, Il9, Il17f,
and Il17a.
AlthoughmicroRNAs are posttranscrip-
tional repressors, they can facilitate the
transcription of genes, for example
through the posttranscriptional repres-
sion of a negative regulator of the genes
in question. Escobar et al. (2014) therefore
searched for miR-155 targets that might
repress cytokine genes. The leading
candidate, Jarid2, is the founding mem-
ber of the Jumonji family of chromatin
modifiers. These proteins remove methyl
groups from lysine residues in histone
tails, and this histone demethylase activity
is important for the regulation of geneexpression. In contrast to other Jumonji
proteins, Jarid2 has amino acid substitu-
tions in its catalytic domain that abolish
histone demethylase activity. Although
catalytically inactive, Jarid2 is neverthe-
less important for embryonic develop-
ment and for embryonic stem cell (ESC)
differentiation, suggesting that in relin-
quishing its histone demethylase activity,
Jarid2 might have acquired novel and
non-redundant functions. Exactly what
these are remains enigmatic, but Jarid2
associates with the polycomb repressive
complex 2 (PRC2) in a range of different
cell types, including ESCs and thymo-
cytes (Landeira and Fisher, 2011). First
discovered as a regulator of Hox genes
in Drosophila, polycomb repressive com-
plexes regulate cellular differentiation
and gene expression by modifying the
state of chromatin (Margueron and Rein-
berg, 2011). In this way, polycomb pro-
teins contribute to gene regulatory events
from the poising of lineage-specific genes
in pluripotent ESCs to Th cell differen-
tiation (Landeira and Fisher, 2011; Tumes
et al., 2013).
At the molecular level, Jarid2 promotes
the recruitment of PRC2 to its target
genes (Figure 1). There is disagreement
about whether Jarid2 also regulates
the methyltransferase activity of PRC2
(Landeira and Fisher, 2011). However,
Jarid2 deficiency is not thought to dere-
press PRC2 target genes. Rather, many
polycomb target genes show reduced
expression and impaired recruitment
of RNA polymerase II in Jarid2-deficient
ESCs. In contrast to PRC2-deficient
ESCs, Jarid2-deficient ESCs have a
severe differentiation block, and it has
therefore been argued that Jarid2 might
have a role independent of conventional
PCR2 components (Landeira and Fisher,
2011).ImmunityThe work of Escobar et al. (2014) links
miR-155-mediated posttranscriptional
regulation of Jarid2 (and probably other
miR-155 targets) to the transcriptional
regulation of cytokine genes in Th17 cells
(Figure 1). Although the paper does not
directly demonstrate that miR-155 targets
Jarid2 (e.g., bymutating putative miR-155
binding sites in the Jarid2 30UTR), this
assertion is supported by computational
predictions and independent experi-
mental studies (Bolisetty et al., 2009).
Escobar et al. (2014) find Jarid2 mRNA
and protein expression elevated approxi-
mately 2-fold in miR-155-deficient Th17
and Treg cells. Such a moderate increase
is not unexpected (microRNAs typically
act as fine tuners rather than on/off
switches) but raises the question how
the dosage of a chromatin protein can
explain the regulation of cytokine genes
in Th17 cells.
To explore the link between Jarid2 and
reduced Il22 expression, Escobar et al.
(2014) polarize control and miR-155-
deficient Th17 cells in vitro. They observe
that the production of interleukin-17 (IL-
17), but not IL-22, by miR-155-deficient
Th17 cells is restored by exogenous IL-
1b, a factor that promotes Th17 cytokine
expression. Chromatin immunoprecipi-
tation experiments showed increased
signal for Jarid2, the PRC2 component
Suz12, and the repressive histone modi-
fication H3K27me3 at the Il22 locus in
miR-155-deficient Th17 cells. Consistent
with lower Il22 expression in the absence
of miR-155, the Il22 promoter showed
reduced occupancy by RNA Polymerase
II. These observations are consistent
with a scenario where the loss of miR-
155 from Th17 cells results in increased
Jarid2 expression, Jarid2 binding and
PRC2 recruitment to the Il22 locus,
increased repressive H3K27me3 histone40, June 19, 2014 ª2014 Elsevier Inc. 855
Figure 1. Jarid2 Links Posttranscriptional Regulation by miR-155 to the Transcriptional
Regulation of Cytokine Genes in Th17 Cells
Jarid2 recruits PRC2, which cooperates with PRC1 (Margueron and Reinberg, 2011). PRC2 and PRC1
repress transcription by catalyzing the repressive histone modifications H3K27me3 and H2AK119ub1, in-
hibiting RNA polymerase II and compacting chromatin. Escobar et al. report that loss of miR-155 results in
elevated Jarid2 expression, increased PRC2 recruitment, and reduced Il22 transcription. In Jarid2-defi-
cient Th17 cells, PRC2 recruitment and repressive histone modifications are reduced, and the expression
of a subset Jarid2 target genes is increased.
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Previewsmodifications, reduced RNA polymerase
II activity, and reduced Il22 expression
(Figure 1). This might be somewhat ideal-
ized and at least in ESCs the situation is
more complex, as Jarid2 promotes the
recruitment not only of PRC2 but also of
RNA polymerase II to a set of develop-
mental regulator genes (Landeira and
Fisher, 2011).
If increased expression of Jarid2 in
miR-155-deficient Th17 cells is respon-
sible for impaired Th17 cytokine expres-
sion, then cytokine expression should
be restored when one or both copies of
the Jarid2 gene are deleted. Escobar
et al. (2014) find that this prediction is
partially upheld. Conditional deletion of
Jarid2 restores the expression of Il17a in
miR-155-deficient Th17 cells but does
not rescue Il22. Because Jarid2 does
not directly bind Il17 loci, restoration of
IL-17 expression is indirect and might
be due to another Jarid2 target, Atf3
(Escobar et al., 2014). The failure of Jarid2
deletion to rescue Il22 expression in
miR-155-deficient Th17 cells complicates
the model that miR-155-mediated regu-
lation of Jarid2 is key to the loss of Il22856 Immunity 40, June 19, 2014 ª2014 Elsevexpression and suggests that additional,
miR-155 targets contribute the regula-
tion of Il22. One candidate is the Il22
repressor c-Maf, which binds the locus
in the absence of Jarid2 (Escobar et al.,
2014).
One of the major challenges in under-
standing the action of transcriptional
regulators is how they are recruited to
specific genes. This is especially critical
when regulation is dose-dependent, as
described for Jarid2 in miR-155-deficient
Th17 cells. Escobar et al. (2014) show
that Il22 and other genes important for
Th17 cells, including Il9, Il10, Eomes,
Tbx21, and Atf3, are targeted by Jarid2
even in control Th17 cells and that
binding merely increased with elevated
Jarid2 dosage when miR-155 is deleted.
Interestingly, Il22, Il9, and Il10 expres-
sion were increased in Jarid2-deficient
Th17 cells (Figure 1). The expression
of other PRC2 target genes was unaf-
fected, suggesting additional layers of
regulation.
The impact of Jarid2 on the activity of
PRC2 might depend on developmental
state: Jarid2 is required not for the self-ier Inc.renewal but for the differentiation of
ESCs, even though Jarid2 itself is down-
regulated during differentiation (Landeira
and Fisher, 2011). Is there a similar role
for Jarid2 in poising genes for future
expression during Th cell differentiation?
Finally, miR-155 expression is highly dy-
namic during T cell activation, and it
would be interesting to know how this
affects the regulation of miR-155 targets
to facilitate changes in the transcriptional
and chromatin landscape of activated
T cells. The finding that microRNAs and
chromatin modifiers form regulatory cir-
cuits to control cytokine gene expression
is exciting and, in the longer term, might
offer opportunities for therapeutic inter-
vention. Th17 cells are important media-
tors of inflammation and both microRNAs
and chromatin modifiers are potential
drug targets.REFERENCES
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